Anti-IgE treatment represents a major breakthrough in the therapeutic management of
severe allergic asthma. Omalizumab is the unique biologic treatment registered for asthma therapy in
children. The clinical efficacy and safety of omalizumab treatment in the pediatric population has
been extensively documented in specific trials and consistently expanded from real-life studies. In
addition, new experimental evidence suggests that omalizumab may also interfere with the cellular
and molecular mechanisms underlying airway remodeling. Novel investigational anti-IgE monoclonal
antibodies with improved pharmacodynamic properties are in the pipeline, potentially offering
alternative mechanisms of modulating IgE pathway.
The aim of this review is to update current knowledge on anti-IgE therapy in pediatric respiratory
Keywords: Allergic rhinitis, asthma, IgE, ligelizumab, MEDI4212, omalizumab, quilizumab, rhinosinusitis.
open access plus
Rights & PermissionsPrintExport